Kingswood Wealth Advisors LLC Invests $281,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Kingswood Wealth Advisors LLC acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 4,484 shares of the company’s stock, valued at approximately $281,000.

Several other hedge funds also recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. increased its position in shares of CRISPR Therapeutics by 18.1% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 39,417 shares of the company’s stock worth $2,468,000 after acquiring an additional 6,039 shares in the last quarter. Raymond James & Associates increased its position in shares of CRISPR Therapeutics by 11.3% in the fourth quarter. Raymond James & Associates now owns 31,839 shares of the company’s stock worth $1,993,000 after acquiring an additional 3,231 shares in the last quarter. HB Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth approximately $207,000. SG Americas Securities LLC increased its position in shares of CRISPR Therapeutics by 107.3% in the fourth quarter. SG Americas Securities LLC now owns 48,013 shares of the company’s stock worth $3,006,000 after acquiring an additional 24,850 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth approximately $328,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CRSP. JMP Securities lifted their target price on shares of CRISPR Therapeutics from $74.00 to $80.00 and gave the stock a “market outperform” rating in a research report on Monday, December 11th. Royal Bank of Canada boosted their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. Needham & Company LLC boosted their price objective on shares of CRISPR Therapeutics from $88.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Chardan Capital boosted their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Finally, TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $74.75.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Samarth Kulkarni sold 50,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at $11,338,182.27. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,410 shares of company stock worth $9,234,677. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Stock Down 2.9 %

NASDAQ CRSP opened at $68.16 on Friday. The company has a 50 day moving average price of $74.02 and a two-hundred day moving average price of $61.87. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The stock has a market capitalization of $5.47 billion, a PE ratio of -34.78 and a beta of 1.79.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. CRISPR Therapeutics had a negative net margin of 240.84% and a negative return on equity of 8.09%. The business had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. During the same period in the previous year, the company earned ($1.41) earnings per share. CRISPR Therapeutics’s revenue for the quarter was up 3253.3% on a year-over-year basis. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.